Immunomedics
This article was originally published in The Gray Sheet
Executive Summary
Patent infringement suit filed in New Jersey federal court alleges that Cytogen's ProstaScint prostate cancer diagnositc imaging agent, co-marketed by Bard, infringes patent 4,460,559 covering antibody-targeted agents for diagnosis and treatment of cancer